<DOC>
	<DOCNO>NCT00002204</DOCNO>
	<brief_summary>To evaluate safety tolerability Chiron vaccine human immunodeficiency virus ( HIV ) p24 ( 25 50 microgram ) /MF59 healthy HIV-1 seronegative adult . To evaluate immunogenicity HIV p24 ( 50 microgram ) /MF59 vaccine .</brief_summary>
	<brief_title>A Phase I , Observer-Blind , Placebo-Controlled Study Chiron Vaccine HIV p24/MF59 Administered Healthy HIV-Seronegative Adults</brief_title>
	<detailed_description>This study evaluate safety immunogenicity Chiron vaccine HIV p24/MF59 . In Part A , 15 volunteer randomly assign receive either HIV p24/MF59 placebo 0 , 1 , 6 month . 10 volunteer receive vaccine 5 volunteer receive placebo . If serious adverse event observe within 1 week first injection first 15 patient , Part B initiate . In Part B , 25 volunteer randomly assign receive HIV p24/MF59 placebo 0 , 1 , 6 month . 20 volunteer receive vaccine 5 volunteer receive placebo .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Inclusion Criteria Volunteers must : Good health determine medical history , physical examination , clinical judgment . Negative serology HIV infection determine licensed HIV ELISA test perform within 6 week prior first immunization . In vitro EpsteinBarr virusimmortalized cell line peripheral blood establish ( require select Part B volunteer ) . Exclusion Criteria Coexisting Condition : Volunteers follow symptoms condition exclude : Significant acute systemic infection . Occupational responsibility would prevent completion participation study . Any condition might interfere evaluation study objective . Volunteers follow prior condition exclude : History immunodeficiency , autoimmune disease , serious chronic illness . Evidence psychiatric medical history substance abuse would adversely affect volunteer 's ability participate trial . History anaphylaxis serious adverse reaction vaccine vaccine component . 1 . Immunosuppressive medication . Live , attenuate vaccine within 60 day study entry . NOTE : Medically indicate subunit kill vaccine ( e.g. , influenza pneumococcal ) exclusionary give least 4 week HIV immunization avoid potential confusion adverse reaction . Experimental agent within 30 day study entry . HIV vaccine MF59 adjuvant . Blood product immunoglobulins past 3 month . Engaging highrisk behavior within 6 month study entry , i.e . : injection drug use , sexual intercourse without condom 4 partner know iv drug user HIV+ partner , newly acquire sexuallytransmitted disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>Reference Values</keyword>
	<keyword>Placebos</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Core Protein p24</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>MF59 oil emulsion</keyword>
</DOC>